{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:06:09Z","timestamp":1793160369479,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"am","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.chest.2020.05.558","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T11:11:22Z","timestamp":1591096282000},"page":"2323-2332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases"],"prefix":"10.1016","volume":"158","author":[{"given":"Amine","family":"Ghembaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","article-title":"Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review","volume":"26","author":"Falagas","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.chest.2020.05.558_bib2","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux","year":"2014","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/qjmed\/hci155","article-title":"Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus","volume":"99","author":"Ng","year":"2006","journal-title":"QJM Mon J Assoc Physicians"},{"issue":"3","key":"10.1016\/j.chest.2020.05.558_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199001183220304","article-title":"The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group","volume":"322","author":"Phair","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"9398","key":"10.1016\/j.chest.2020.05.558_bib5","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","article-title":"Glucocorticoids and invasive fungal infections","volume":"362","author":"Lionakis","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2334-4-42","article-title":"Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention","volume":"4","author":"Sowden","year":"2004","journal-title":"BMC Infect Dis"},{"issue":"35","key":"10.1016\/j.chest.2020.05.558_bib7","doi-asserted-by":"crossref","first-page":"59729","DOI":"10.18632\/oncotarget.19927","article-title":"Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","article-title":"Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality","volume":"42","author":"Ward","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"3 pt 1","key":"10.1016\/j.chest.2020.05.558_bib9","first-page":"795","article-title":"Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener\u2019s granulomatosis","volume":"151","author":"Ognibene","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.chest.2020.05.558_bib10","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/art.1780401213","article-title":"A\u00a0prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener\u2019s granulomatosis","volume":"40","author":"Guillevin","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.semarthrit.2010.08.003","article-title":"Infectious complications in polymyositis and dermatomyositis: a series of 279 patients","volume":"41","author":"Marie","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/art.21083","article-title":"Opportunistic infections in polymyositis and dermatomyositis","volume":"53","author":"Marie","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/1756-185X.13255","article-title":"Opportunistic infections in patients with idiopathic inflammatory myopathies","volume":"21","author":"Redondo-Benito","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"14","key":"10.1016\/j.chest.2020.05.558_bib15","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0961203317703494","article-title":"Low prevalence of Pneumocystis pneumonia in hospitalized patients with systemic lupus erythematosus: review of a clinical data warehouse","volume":"26","author":"Kapoor","year":"2017","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00296-008-0721-6","article-title":"Risk factors of Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus","volume":"29","author":"Lertnawapan","year":"2008","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144918","article-title":"National lupus hospitalization trends reveal rising rates of herpes zoster and declines in pneumocystis pneumonia","volume":"11","author":"Murray","year":"2016","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.chest.2020.05.558_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/RHU.0000000000000731","article-title":"Risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis and a prophylactic indication of trimethoprim\/sulfamethoxazole","volume":"24","author":"Yukawa","year":"2018","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.medmal.2014.01.007","article-title":"Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients","volume":"44","author":"Roux","year":"2014","journal-title":"M\u00e9decine Mal Infect"},{"issue":"24","key":"10.1016\/j.chest.2020.05.558_bib20","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2020.05.558_bib21","first-page":"478","article-title":"Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection","volume":"41","author":"Su","year":"2008","journal-title":"J\u00a0Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.chest.2020.05.558_bib23","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"Clair","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","article-title":"Safety of tumour necrosis factor-\u03b1 antagonists","volume":"27","author":"Khanna","year":"2004","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4065\/71.1.5","article-title":"Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illnesses and prior corticosteroid therapy","volume":"71","author":"Yale","year":"1996","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib26","first-page":"671","article-title":"Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience","volume":"35","author":"Mecoli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/acr.20435","article-title":"Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series","volume":"63","author":"Kermani","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"49","key":"10.1016\/j.chest.2020.05.558_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008846","article-title":"Severe infections in sarcoidosis: incidence, predictors and long-term outcome in a cohort of 585 patients","volume":"96","author":"Dur\u00e9ault","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.chest.2020.05.558_bib29","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jaad.2018.12.052","article-title":"Incidence of pneumocystosis among patients exposed to immunosuppression","volume":"80","author":"Rekhtman","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.chest.2020.05.558_bib30","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780390906","article-title":"Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus","volume":"39","author":"Pryor","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1399-3062.2009.00407.x","article-title":"Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity","volume":"11","author":"Ritter","year":"2009","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/340867","article-title":"The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials","volume":"35","author":"Husain","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AAC.41.1.40","article-title":"IMP dehydrogenase from Pneumocystis carinii as a potential drug target","volume":"41","author":"O\u2019Gara","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"10.1016\/j.chest.2020.05.558_bib34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2020.05.558_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.chest.2020.05.558_bib37","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A\u00a0phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"10155","key":"10.1016\/j.chest.2020.05.558_bib38","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2020.05.558_bib40","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs\u00a0placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.chest.2020.05.558_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2020.05.558_bib42","first-page":"1186","article-title":"Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis\/dermatomyositis or systemic lupus erythematosus","volume":"23","author":"Kadoya","year":"1996","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2020.05.558_bib43","first-page":"1191","article-title":"Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia","volume":"19","author":"Porges","year":"1992","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.chest.2020.05.558_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/ard.54.12.991","article-title":"Factors associated with Pneumocystis carinii pneumonia in Wegener\u2019s granulomatosis","volume":"54","author":"Godeau","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.chest.2020.05.558_bib45","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2017.02.010","article-title":"Pneumocystis pneumonia in patients with inflammatory or autoimmune diseases: usefulness of lymphocyte subtyping","volume":"57","author":"Li","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semarthrit.2015.01.007","article-title":"Pneumocystis jirovecci pneumonia in connective tissue diseases: comparison with other immunocompromised patients","volume":"45","author":"Teichtahl","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2020.05.558_bib47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3109\/s10165-012-0796-5","article-title":"Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients","volume":"23","author":"Watanabe","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"10.1016\/j.chest.2020.05.558_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.24283","article-title":"Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients","volume":"61","author":"Komano","year":"2009","journal-title":"Arthritis Care Res"},{"issue":"6","key":"10.1016\/j.chest.2020.05.558_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1128\/CMR.00013-12","article-title":"Colonization by Pneumocystis jirovecii and its role in disease","volume":"25","author":"Morris","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"16","key":"10.1016\/j.chest.2020.05.558_bib51","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1503\/cmaj.111152","article-title":"Considerations when prescribing trimethoprim-sulfamethoxazole","volume":"183","author":"Ho","year":"2011","journal-title":"CMAJ"},{"issue":"9","key":"10.1016\/j.chest.2020.05.558_bib52","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1093\/jac\/dkw157","article-title":"ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","volume":"71","author":"Maertens","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib53","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/jac\/dks504","article-title":"Antimalarial pharmacology and therapeutics of atovaquone","volume":"68","author":"Nixon","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1399-3062.2002.t01-1-00008.x","article-title":"Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation","volume":"4","author":"Marras","year":"2002","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"10.1016\/j.chest.2020.05.558_bib55","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0196-0644(05)81912-2","article-title":"Torsade de pointes after inhaled pentamidine","volume":"21","author":"Engrav","year":"1992","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D330M4B5KR","article-title":"Dapsone","volume":"8","author":"Wolf","year":"2002","journal-title":"Dermatol Online J"},{"issue":"9","key":"10.1016\/j.chest.2020.05.558_bib57","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"10.1016\/j.chest.2020.05.558_bib59","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJM198706253162604","article-title":"Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"316","author":"Hughes","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1086\/520433","article-title":"A\u00a0randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)","volume":"29","author":"El-Sadr","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-016-1206-8","article-title":"Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial","volume":"19","author":"Utsunomiya","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.chest.2020.05.558_bib62","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2215\/CJN.08140718","article-title":"Clinical pharmacology of antibiotics","volume":"14","author":"Eyler","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.chest.2020.05.558_bib63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"Kitazawa","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"issue":"11","key":"10.1016\/j.chest.2020.05.558_bib64","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/cid\/cit071","article-title":"Has the time come for routine trimethoprim-sulfamethoxazole prophylaxis in patients taking biologic therapies?","volume":"56","author":"Bodro","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.chest.2020.05.558_bib65","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1001\/archinte.1991.00400080133026","article-title":"Treatment of Wegener\u2019s granulomatosis with sulfamethoxazole-trimethoprim","volume":"151","author":"Valeriano-Marcet","year":"1991","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.7326\/0003-4819-120-1-199401010-00003","article-title":"Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis","volume":"120","author":"Stegeman","year":"1994","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener\u2019s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2020.05.558_bib68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2020.05.558_bib69","first-page":"246","article-title":"Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases","volume":"21","author":"Godeau","year":"1994","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib70","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2007.05.015","article-title":"Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century","volume":"30","author":"Rolain","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.chest.2020.05.558_bib71","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3899\/jrheum.090843","article-title":"A\u00a0survey of rheumatologists\u2019 practice for prescribing pneumocystis prophylaxis","volume":"37","author":"Cettomai","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2020.05.558_bib72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0049-0172(75)90024-4","article-title":"Drug-induced systemic lupus erythematosus: a critical review","volume":"5","author":"Lee","year":"1975","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.chest.2020.05.558_bib73","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220316238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220316238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:27:26Z","timestamp":1757924846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220316238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0012369220316238"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.05.558","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors and Prevention of Pneumocystis jirovecii Pneumonia in Patients With Autoimmune and Inflammatory Diseases","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.05.558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}